Neuralace Medical

NeuraLace operates at the intersection of medical devices, neuromodulation, and chronic-pain therapeutics. Its principal product, Axon Therapy mPNS, targets neuropathic pain through short, non-invasive magnetic stimulation sessions. The company’s differentiation is the combination of a drug-free treatment model, no implanted leads or electrodes, and FDA clearance for chronic painful diabetic neuropathy. That approach contrasts with medication-centered pain management and with more invasive spinal-cord or peripheral-nerve stimulation systems, but the available profile does not identify specific company competitors by name. NeuraLace therefore appears to compete across several categories rather than within a single narrowly defined device segment. Its market challenge is likely to involve clinical adoption, physician training, reimbursement, and evidence generation as much as technical performance. The May 2024 focus on CMS expansion is particularly relevant because payer coverage can determine whether a non-invasive therapy moves beyond specialist use. Five granted patents and two registered trademarks provide an identifiable intellectual-property base, while the Neuralace SEAT Safety and Efficacy trial indicates an emphasis on clinical validation. With approximately 11–50 employees and $3.85 million in recorded total funding, the company remains materially smaller than established device manufacturers and is still in an expansion phase.

NeuraLace’s trajectory shows a progression from early device development to regulatory clearance and commercialization planning. The company was founded in October 2016 and raised an $850,000 seed round in March 2017, followed by a $3 million seed round in June 2019. A Series A was announced in September 2021, and Keith Warner was appointed chief executive officer in March 2022. A further funding event was announced on January 20, 2023; its amount is not presented consistently across the company profile, although one financial signal describes a $3.1 million first close. The recorded structured-company total remains $3.85 million across four rounds, so the 2023 amount should be treated cautiously. The January 2024 FDA clearance of Axon Therapy for painful diabetic neuropathy marks the clearest inflection point, moving the business from development toward clinical deployment. May 2024 coverage about expansion through CMS points to reimbursement as the next growth gate. A June 2025 market appearance suggests continued relevance in peripheral-neuropathy treatment discussions.